

TECH CENTER 1600 2900
RECEIVED
APR 7 1 00 PM
SHEET OF 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO
AMBIINC.006A

APPLICATION NO
10/001,684

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT
David P. Katz

FILING DATE
October 25, 2001

GROUP
1614

APR 19 2002
PATENT & TRADEMARK OFFICE

SEE SEVERAL SHEETS IF NECESSARY)

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
PP	1.	Re. 33,988	07/07/92	Evans			
↑	2.	4,954,492	09/04/90	Jensen			
↑	3.	5,087,623	02/11/92	Boynton et al.			
↑	4.	5,087,624	02/11/92	Boynton et al.			
↑	5.	5,175,156	12/29/92	Boynton et al.			
↑	6.	5,194,615	03/16/93	Jensen			
↓	7.	5,543,405	08/06/96	Keown et al.			
PP	8.	5,789,401	08/04/98	McCarty			

FOREIGN PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							YES	NO	
PP	9.	WO 96/35421	11/14/96	PCT					

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PP	10.	Anderson (1986) Chromium metabolism and its role in disease processes in man. Clinical Physiology and Biochemistry. Abstract in 1 page.
PP	11.	Atkinson (2000) Clinical implications for CLA in the treatment of obesity. Richard L. Atkinson, M.D., Professor of Medicine and Nutritional Sciences, University of Wisconsin, Madison, WI. 1 page.
PP	12.	Bauer et al. (1998) Coated pharmaceutical dosage forms: Fundamentals, manufacturing techniques, biopharmaceutical aspects, test methods and raw materials. CRC Press, Washington, DC. 81-85.
PP	13.	Boyle, Jr. et al. (1977) Chromium depletion in the pathogenesis of diabetes and atherosclerosis. 1977) Southern Medical Journal. 70(12):1449-1453.
PP	14.	Bridges et al. (1983) Standards for ovarian volume in childhood and puberty. Fertility and Sterility. 60(3):456-460.
PP	15.	Burghen et al. (1980) Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab. 50(1):113-116.
PP	16.	Carmina et al. (1992) Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol. 167:1807-1812.
PP	17.	Carstensen, J.T. (1993) Pharmaceutical principles of solid dosage forms. Technomic Publishing Co., Inc., Lancaster, PA. 228-230.
PP	18.	Cefalu et al. (1999) Effect of chromium picolinate on insulin sensitivity in vivo. J Trace Elem Exp Med. 12:71-83.
PP	19.	Davis et al. (1995) Effects of over-the-counter drugs on chromium retention and urinary excretion in rats. Nutrition Research. 15(2) 201-210.
PP	20.	Dunaif et al. (1987) Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab. 65(3):499-507.
PP	21.	Dunaif et al. (1996) The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 81(9):3299-3306.

EXAMINER *Patricia D. Galt* DATE CONSIDERED 7/17/02

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

RECEIVED

TECH CENTER 1600 2900
APR 19 2002
SHEET 2 OF 2
RECEIVED

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. AMBIINC 006A	APPLICATION NO. 10/001,684
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT David P. Katz	
		FILING DATE October 25, 2001	GROUP 1614

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
PP	22. Dunaif, A. (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews. 18(6):774-800.
PP	23. Ehrmann et al. (1997) Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82(2):5224-530.
PP	24. Ehrmann et al. (1997) Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82(7):2108-2116.
PP	25. Givens et al. (1974) Remission of acanthosis nigricans associated with polycystic ovarian disease and a stromal luteoma. J Clin Endocrinol Metab. 38(3):347-355.
PP	26. Kaats et al. (1998) A randomized, double-masked, placebo-controlled study of the effects of chromium picolinate supplementation on body composition: a replication and extension of a previous study. Current Therapeutic Research. 59(6):379-388.
PP	27. Kahn et al. (1976) The syndromes of insulin resistance and acanthosis nigricans. N Engl J Med. 294:(14)739-745.
PP	28. Kamath et al. (1997) Absorption, retention and urinary excretion of chromium-51 in rats pretreated with indomethacin and dosed with dimethylprostaglandin E ₂ , misoprostol or prostacyclin ^{1,2,3} . J Nutr. 127:478-482.
PP	29. Lobo et al. (1983) Elevated bioactive luteinizing hormone in women with the polycystic ovary syndrome. Fertil Steril. 39(5):674-678.
PP	30. Nestler et al. (1989) Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 68(6):1027-1032.
PP	31. Park et al. (1999) Conjugated Linoleic Acid (CLA). Food Research Institute. pp 48-56.
PP	32. Pi-Sunyer et al. (1984) Chromium. Nutrition Reviews' Present Knowledge in Nutrition, Fifth Edition. The Nutrition Foundation, Inc., Washington, D.C. 571-577.
PP	33. Polson et al. (1988) Polycystic ovaries-a common finding in normal women. The Lancet. 870-872.
PP	34. Singh et al. (1986) Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agent. Agents and Actions. 18:407-412.
PP	35. Stein et al. (1935) Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 29:181-191.
PP	36. Recommended Daily Allowances, Ninth Revised Edition, 1980. National Academy of Sciences, Washington, D.C.

S:\DOCS\MKD\MKD-2686.DOC\041202

EXAMINER	DATE CONSIDERED 7/17/02
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	